カテゴリ： GlobalData, スイス, 企業調査

Lonza Group Ltd (LONN)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Lonza Group Ltd (LONN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012228
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：107
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：スイス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Lonza Group Ltd (Lonza) is a biopharmaceutical company that manufactures and develops chemical and biological active pharmaceutical ingredients, and other products and services. The company offers active pharmaceutical ingredients, stem cell therapies, drinking water sanitizers, vitamin B compounds, industrial preservatives, microbial control solutions and organic personal care ingredients. It also provides custom development and custom manufacturing services to its clients. Lonza’s client base includes professionals in the biotechnology, pharmaceutical, academic, and government research industries; manufacturers of health and consumer products; distributors; formulators and service companies. The company’s key markets include bioresearch, nutrition, pharma and biotech, microbial control, agriculture, materials science and personal care industries. It operates several manufacturing and research and development (R&D) facilities across Asia, Europe and Americas. Lonza is headquartered in Basel, Switzerland.

Lonza Group Ltd (LONN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Lonza Group Ltd, Medical Devices Deals, 2011 to YTD 2017 12
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Lonza to Acquire Mammalian Manufacturing Site from Shire 16
Capsugel Acquires Ionic Liquids Technology from Monash University 17
InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18
Capsugel Acquires FlexTab Technology From GlaxoSmithKline 19
Venture Financing 20
Odyssey Thera Raises US$3 Million In Venture Financing 20
Private Equity 21
Kainos Capital Acquires InterHealth Nutraceuticals 21
Kohlberg Kravis Completes Acquisition Of Capsugel From Pfizer 22
Partnerships 24
BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 24
Capsugel Enters into Agreement with Pulmatrix 25
Lonza Enters into Agreement with Kodiak Sciences 26
CiMaas Enters into Agreement with PharmaCell 27
Lonza Partners with Octane Biotech 28
Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 29
Lonza and AMYRA Biotech Enter into Agreement 30
Quotient Clinical Enters Into Co-Development Agreement With Capsugel 31
Catalent Pharma Solutions Enters Into Agreement With Bend Research 32
CSIRO Enters Into Co-Development Agreement With Lonza 33
Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 34
Lonza Enters Into Co-Marketing Agreement With Lipogen For Phosphatidylserine-Based Formulas 35
Shanghai Fosun Enters Into Joint Venture Agreement With Lonza Group 36
Bend Research Enters Into An Agreement With Xcelience 37
Critical Outcome Technologies and Xcelience Enter into Agreement 38
Athera Biotechnologies Enters Into Co-Development Agreement With Lonza 39
Licensing Agreements 40
Xbiotech Enters into Licensing Agreement with Lonza Sales 40
Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 41
Pierre Fabre Enters into Licensing Agreement with Lonza 43
Pierre Fabre Enters into Licensing Agreement with Lonza 44
CytoDyn Enters into Licensing Agreement with Lonza Sales 45
Lonza Enters into Licensing Agreement with arGEN-X 46
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 47
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 48
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 49
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 50
Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 51
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 52
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 53
Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 54
Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 55
Bend Research Enters Into Licensing Agreement With Merck 56
Oxford BioTherapeutics Enters Into Licensing Agreement With Lonza 57
Enzymicals Enters Into Licensing Agreement With Lonza For (R)-selective Transaminases 58
Lonza Enters Into License Agreement With ORGANOBALANCE 59
Equity Offering 60
Lonza Raise USD2.24 Billion in Rights Offering of Shares 60
Lonza Raises USD871 Million in Private Placement of Shares 61
Lonza Group Completes IPO Of Common Stock On Singapore Exchange 62
Debt Offering 63
Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 63
Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For US$316.5 Million 64
Lonza Completes Public Offering Of Bonds Due 2022 For US$112 Million 65
Lonza Completes Public Offering Of Bonds Due 2018 For US$213 Million 66
Lonza Completes Public Offering Of Bonds Due 2015 For US$266 Million 67
Lonza Completes Public Offering Of Bonds Due 2018 For US$155 Million 68
Asset Transactions 69
PolyPeptide to Acquire Peptides Business and Operations in Braine, Belgium from Lonza 69
Acquisition 70
Lonza Group Acquires micromacinazione from Cross 70
Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 71
Lonza Group Acquires PharmaCell 73
Lonza Acquires HansaBioMed Life Sciences 74
Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 75
Lonza May Acquire Catalent 76
Capsugel Acquires Xcelience 77
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 78
PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 79
Capsugel Completes Acquisition Of Bend Research, Drug Delivery Technologies Company 80
Capsugel Belgium Acquires Encap Drug Delivery 81
Lonza Group Ltd – Key Competitors 82
Lonza Group Ltd – Key Employees 83
Lonza Group Ltd – Locations And Subsidiaries 84
Head Office 84
Other Locations & Subsidiaries 84
Joint Venture 87
Recent Developments 88
Strategy And Business Planning 88
Aug 24, 2017: Lonza to Increase and Expand Capabilities for Drug Product Services for Parenteral Dosage Forms 88
Feb 02, 2016: Lonza to Build Capabilities for Drug Product Development Services, Enabling One-Stop-Shop Solutions for Customers 89
Financial Announcements 90
Oct 26, 2017: Lonza Reports a Strong Third Quarter and Capsugel Integration on Track 90
Jul 26, 2017: Lonza Delivers Strong Performance in First Half 2017 and Sets a Strong Foundation for Continued Attractive Mid-Term Growth 92
Jan 25, 2017: Lonza Reports Record-Breaking Financial Performance, Resulting in 24.2% CORE EBIT Growth, Driven by Pharma and Biotech 94
Apr 26, 2016: Lonza Reports Record First Quarter 96
Jan 27, 2016: Lonza Reports Strong Sales and Profit Growth in 2015 97
Corporate Communications 99
Jun 27, 2017: Lonza’s CHRO Elected to Board of Advance Women in Swiss Business 99
Jan 25, 2017: Lonza Appoints Fridtjof Helemann, CHRO, to Executive Committee 100
May 10, 2016: Rodolfo Savitzky appointed as new CFO for Lonza to succeed Toralf Haag who was appointed as CFO of the Voith in Germany 101
Mar 23, 2016: Lonza Consumer Care Announces Appointment of Dr. Russell Elliott PhD as Director of Skin Care Technology 102
Product News 103
Nov 08, 2017: Lonza Launches XS Pichia 2.0 Expression and Manufacturing Platform for Development of Next Generation Therapeutics 103
Sep 07, 2016: Lonza Releases Second-Generation Immunogenicity Assessment and Optimization Platform for Development of Therapeutic Proteins, Vaccines and Cell Therapies 104
Mar 30, 2016: Lonza Launches Sentinel APART Server-Based Platform Designed to Help Improve the Quality and Safety of Therapeutic Antibodies 105
Other Significant Developments 106
May 17, 2016: Lonza CytoSMART Lab Free-Trial Initiative Launched 106
Appendix 107
Methodology 107
About GlobalData 107
Contact Us 107
Disclaimer 107

List of Tables
Lonza Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Lonza Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Lonza Group Ltd, Deals By Therapy Area, 2011 to YTD 2017 11
Lonza Group Ltd, Medical Devices Deals, 2011 to YTD 2017 12
Lonza Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Lonza to Acquire Mammalian Manufacturing Site from Shire 16
Capsugel Acquires Ionic Liquids Technology from Monash University 17
InterHealth Nutraceuticals Acquires 7-Keto from Humanetics 18
Capsugel Acquires FlexTab Technology From GlaxoSmithKline 19
Odyssey Thera Raises US$3 Million In Venture Financing 20
Kainos Capital Acquires InterHealth Nutraceuticals 21
Kohlberg Kravis Completes Acquisition Of Capsugel From Pfizer 22
BaroFold Enters Into Licensing Agreement with Lonza For PreEMT Technology 24
Capsugel Enters into Agreement with Pulmatrix 25
Lonza Enters into Agreement with Kodiak Sciences 26
CiMaas Enters into Agreement with PharmaCell 27
Lonza Partners with Octane Biotech 28
Capsugel Enter into Co-Development Agreement with Cardax for Astaxanthin Products 29
Lonza and AMYRA Biotech Enter into Agreement 30
Quotient Clinical Enters Into Co-Development Agreement With Capsugel 31
Catalent Pharma Solutions Enters Into Agreement With Bend Research 32
CSIRO Enters Into Co-Development Agreement With Lonza 33
Lonza Enters Into Co-Development Agreement With Agennix For Talactoferrin 34
Lonza Enters Into Co-Marketing Agreement With Lipogen For Phosphatidylserine-Based Formulas 35
Shanghai Fosun Enters Into Joint Venture Agreement With Lonza Group 36
Bend Research Enters Into An Agreement With Xcelience 37
Critical Outcome Technologies and Xcelience Enter into Agreement 38
Athera Biotechnologies Enters Into Co-Development Agreement With Lonza 39
Xbiotech Enters into Licensing Agreement with Lonza Sales 40
Biowa And Lonza Enter into Licensing Agreement with arGEN-X for Potelligent CHOK1SV 41
Pierre Fabre Enters into Licensing Agreement with Lonza 43
Pierre Fabre Enters into Licensing Agreement with Lonza 44
CytoDyn Enters into Licensing Agreement with Lonza Sales 45
Lonza Enters into Licensing Agreement with arGEN-X 46
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 47
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 48
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 49
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 50
Lonza Walkersville Enters Into Licensing Agreement With iPS Academia Japan 51
Five Prime Therapeutics Enters Into Licensing Agreement With BioWa And Lonza For Potelligent CHOK1SV Cell Line 52
Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 53
Bend Research Enters Into Licensing Agreement With Affinium For SDD Technology 54
Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 55
Bend Research Enters Into Licensing Agreement With Merck 56
Oxford BioTherapeutics Enters Into Licensing Agreement With Lonza 57
Enzymicals Enters Into Licensing Agreement With Lonza For (R)-selective Transaminases 58
Lonza Enters Into License Agreement With ORGANOBALANCE 59
Lonza Raise USD2.24 Billion in Rights Offering of Shares 60
Lonza Raises USD871 Million in Private Placement of Shares 61
Lonza Group Completes IPO Of Common Stock On Singapore Exchange 62
Lonza Prices Public Offering of 0.125% Bond Due 2021 for USD253.7 Million 63
Lonza Completes Public Offering Of 1.75% Bonds Due 2019 For US$316.5 Million 64
Lonza Completes Public Offering Of Bonds Due 2022 For US$112 Million 65
Lonza Completes Public Offering Of Bonds Due 2018 For US$213 Million 66
Lonza Completes Public Offering Of Bonds Due 2015 For US$266 Million 67
Lonza Completes Public Offering Of Bonds Due 2018 For US$155 Million 68
PolyPeptide to Acquire Peptides Business and Operations in Braine, Belgium from Lonza 69
Lonza Group Acquires micromacinazione from Cross 70
Lonza Acquires Capsugel from KKR & Co for USD5.5 Billion 71
Lonza Group Acquires PharmaCell 73
Lonza Acquires HansaBioMed Life Sciences 74
Lonza Acquires InterHealth Nutraceuticals from Kainos Capital for USD300 Million 75
Lonza May Acquire Catalent 76
Capsugel Acquires Xcelience 77
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 78
PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 79
Capsugel Completes Acquisition Of Bend Research, Drug Delivery Technologies Company 80
Capsugel Belgium Acquires Encap Drug Delivery 81
Lonza Group Ltd, Key Competitors 82
Lonza Group Ltd, Key Employees 83
Lonza Group Ltd, Subsidiaries 84
Lonza Group Ltd, Joint Venture 87

★海外企業調査レポート[Lonza Group Ltd (LONN)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Companhia de Saneamento Basico do Estado de Sao Paulo (SBSP3)：企業の財務・戦略的SWOT分析
    Summary Companhia de Saneamento Basico do Estado de Sao Paulo (SABESP) is an environmental consulting company that is responsible for supplying water and collecting and treating sewage in municipalities of Sao Paulo state. The company provides water and sewage services in another four municipalities …
  • EMCOR Group Inc (EME)：企業の財務・戦略的SWOT分析
    EMCOR Group Inc (EME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Mazda Motor Corp (7261)：企業の財務・戦略的SWOT分析
    Mazda Motor Corp (7261) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Wake Forest Innovations：製薬・医療：M&Aディール及び事業提携情報
    Summary Wake Forest Innovations (Wake Forest), a subsidiary of Wake Forest Baptist Medical Center, is a health care service provider. The center offers development and commercialization of discoveries; services; and products such as medicines and vaccines, from the Medical Center and Wake Forest Uni …
  • Aurora Health Care Inc：企業の戦略的SWOT分析
    Aurora Health Care Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Egmont International Holding AS：企業の戦略的SWOT分析
    Egmont International Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • African Development Bank Group：企業の戦略的SWOT分析
    African Development Bank Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • OncoSil Medical Ltd (OSL)-医療機器分野：企業M&A・提携分析
    Summary OncoSil Medical Ltd (OncoSil), formerly NeuroDiscovery Ltd is a medical device company that develops and commercializes treatments for patients with pancreatic and liver cancer. The company’s lead product include oncosil, a brachytherapy device that emits beta radiation and is implanted dire …
  • Eversource Energy：発電所・企業SWOT分析
    Eversource Energy – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • The Warehouse Group Ltd (WHS)：企業の財務・戦略的SWOT分析
    The Warehouse Group Ltd (WHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Torii Pharmaceutical Co Ltd (4551)：製薬・医療：M&Aディール及び事業提携情報
    Summary Torii Pharmaceutical Co Ltd (Torii) a subsidiary of Japan Tobacco Inc is a healthcare product provider that manufactures and markets products such as antebate ointment, antebate cream and urinorm used for the treatment of hyperuricemia and gout. The company offers products for the treatment …
  • Comstock Resources Inc (CRK)：企業の財務・戦略的SWOT分析
    Summary Comstock Resources Inc (Comstock) is an oil and gas company. It acquires, develops, explores and produces oil and natural gas properties. The company provides oil and gas operations such as Eagle ford Shale, Haynesville Shale and Bakken Shale in North Dakota and Montana; and North Louisiana, …
  • Gray Television, Inc. (GTN)：企業の財務・戦略的SWOT分析
    Gray Television, Inc. (GTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Ceska pojistovna a.s.：企業の戦略的SWOT分析
    Ceska pojistovna a.s. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Ubiquiti Networks Inc
    Ubiquiti Networks Inc - Strategy, SWOT and Corporate Finance Report Summary Ubiquiti Networks Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sirona Biochem Corp (SBM)：企業の財務・戦略的SWOT分析
    Summary Sirona Biochem Corp (Sirona Biochem) is a biotechnology company that discovers and develops therapeutics, cosmeceuticals and biological ingredients. The company develops drugs for diabetes and cancer. It provides cosmeceutical programs such as development of anti-aging and depigmenting agent …
  • Deutsche Telekom AG (DTE)：企業の財務・戦略的SWOT分析
    Deutsche Telekom AG (DTE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Pelago Bioscience AB：製薬・医療：M&Aディール及び事業提携情報
    Summary Pelago Bioscience AB (Pelago Bioscience) is a developer of patented cellular thermal shift assay for use in determination and quantification of drug–target interactions. The company utilizes patented CETSA technology which enables direct, in situ physiologically relevant measurements of targ …
  • Hrvatska Elektroprivreda dd：電力：M&Aディール及び事業提携情報
    Summary Hrvatska Elektroprivreda dd (HEP) is an energy utility. Through its subsidiaries and affiliates, the company generates, transmits, distributes, and sells electricity and thermal energy; and distributes and sells natural gas on wholesale and retail basis. It produces electricity using hydro, …
  • Hotel Dubrovnik d.d.：企業の戦略・SWOT・財務分析
    Hotel Dubrovnik d.d. - Strategy, SWOT and Corporate Finance Report Summary Hotel Dubrovnik d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆